Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on February 20, 2020, covering events occurring between February 20, 2020, and February 26, 2020. The Company is an emerging growth company incorporated in Delaware. The filing primarily addresses new debt financing, unregistered equity issuances, and executive departures.
Key Financial Metrics
- New Debt: Borrowed an aggregate of $353,761.99 from John M. Desmarais between February 20 and February 26, 2020.
- Debt Terms: Interest rate of 12% per annum; payable on demand on or after March 10, 2020.
- Collateral: Loans are secured by a security interest in substantially all of the Company's assets.
- Historical Debt (as of Sept 30, 2019): $8,496,076 outstanding.
- Debt Reduction (post-Sept 30, 2019): $1,174,020 converted to equity; $1,358,000 repaid.
- Recent Financing (post-Sept 30, 2019): $520,000 in equity proceeds and $2,167,387 in debt proceeds (including the new loans).
- Recent Revenue (post-Sept 30, 2019): $32,000.
- Historical Losses: Net losses of $5,056,973 (3 months ended Sept 30, 2019) and $13,097,335 (9 months ended Sept 30, 2019).
- Working Capital/Equity Deficiency (as of Sept 30, 2019): Working capital deficiency of $13,514,377; Stockholders' deficiency of $12,428,533.
- Equity Issuance: Issued 366,721,142 shares of common stock upon conversion of $366,721 in indebtedness.
- Shares Outstanding: Approximately 1,694,551,051 shares issued and outstanding following the conversion.
Material Changes
- Capital Structure: Significant dilution occurred with the issuance of over 366 million shares to settle convertible debt.
- Liquidity Position: The Company continues to incur substantial losses and relies on new debt and equity financing to operate.
- Management: Lance Alstodt, Executive Vice President and Chief Strategy Officer, was terminated on February 24, 2020.
- Related Party Transactions: New loans were obtained from John M. Desmarais, a former director who resigned on January 10, 2020.
Outlook, Risks, and Contingencies
- Going Concern: The filing explicitly states that substantial doubt exists regarding the Company's ability to continue as a going concern due to working capital deficiencies, stockholders' deficiencies, and continued substantial losses.
- Debt Maturity: The new notes are payable on demand starting March 10, 2020, creating immediate liquidity pressure.
- Security Interest: The Company has granted a security interest in substantially all assets to secure the new loans, limiting future borrowing capacity against those assets.
Investor Verification Checklist
- Verify the Company's ability to repay the $353,761.99 loan on demand after March 10, 2020, given the stated going concern doubt.
- Confirm the impact of the 366 million share issuance on existing shareholder dilution and the total authorized share count (2 billion authorized).
- Review the full text of the Security Agreement (Exhibit 10.3) to understand the scope of assets pledged as collateral.
- Assess the operational impact of the termination of the Executive Vice President and Chief Strategy Officer.
- Monitor subsequent filings for updates on the $13.5 million working capital deficiency and ongoing loss trends.